Ketamine, mushrooms and therapeutic use

Peter Boghossian presses Dr. Drew on the treatments medicine won't touch, including ibogaine for opioid addiction, peptides, GLP-1 risks, and hormone replacement therapy. Dr. Drew doesn't hedge. What emerges is an argument for evidence-based medicine in an era of regulatory timidity, and with Trump's executive order on psychedelics, that conversation just became more urgent. The discussion ends where it should, not with longevity hacks, but with the question of what makes a life worth living.

For more Dr. Drew Website

Follow Peter Boghossin for more.